This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Nektar Therapeutics

Drug Names(s): PEG-hGHra, pegvisomant

Description: Somavert is an inhibitor of the growth hormone receptor.

Deal Structure: DRI Capital
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Somavert for acromegaly. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.

Partners: Pfizer Inc. DRI Capital Inc.

Somavert News

Pink Sheet Pharmacia Somavert

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug